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ABSTRACT

EXPLORATION OF FLUORINATED α,β-DEHYDROAMINO ACIDS
AND THEIR STRUCTURE

Austin LeSueur
Department of Chemistry and Biochemistry
Bachelor of Science

This thesis explores the synthesis of fluorinated α,β-dehydroamino acids,
specifically a fluorinated dehydrovaline derivative. Previous work has been done on the
equivalent dehydrovaline derivative without fluorine present and this work builds toward
the fluorinated version with the goal of comparing the two structurally. The synthesis
presented here pulls from previous synthetic strategies employed for dehydrovaline while
also exploring the synthetic impact of the electronegative fluorine atoms.
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Introduction
In organic chemistry, much of what we do is inspired by our observations of
nature. For example, our synthetic targets are often natural products and we regularly
seek inspiration from the biosynthetic pathway that the organism itself uses to make the
product. Even some of the completely novel molecules we make are designed to mimic
naturally occurring compounds or fit into a known protein binding site. And nowhere is
the natural inspiration more prevalent than in the pharmaceutical industry.
By looking at our own biology and that of other organisms we can take advantage
of millennia of evolution to help us increase our knowledge of pharmaceutical chemistry.
Every species has developed its own ways of fighting infections and regulating internal
problems in order to survive, so there is plenty of material to pull from. One prevalent
type of molecule involved in these processes is the peptide. Peptides are present in
everything from antimicrobial defenses to cell signaling in our bodies, so understanding
them better should open up new opportunities for peptide-based drugs.
There are, however, some downsides to peptide pharmaceuticals and despite all
their potential only a few have made their way into mainstream use. The main problem is
that our digestive systems are very good at breaking down proteins and that includes
peptide pharmaceuticals. This means that these peptides are not viable oral
pharmaceuticals without some sort of protection mechanism. Researchers have tried to
circumvent this problem by administering the drugs intravenously, by inhaling, through
the nose, or even by coating them in a liposome.1 Unfortunately, most of these methods
have proven impractical and new strategies are needed if we are to take full advantage of
the wealth of options nature has given us.
1

Researchers have also experimented with various methods of modifying the
peptides themselves to increase proteolytic resistance. Proteases, the enzymes
responsible for cutting up peptides, can attack peptides much more easily if the peptide is
unfolded than if it is folded,2 so finding a way to keep peptides in their folded
conformation should increase their half-life in the body. Many methods for doing this
have been proposed such as peptoids,3 β and α/β peptides,4 stapled peptides,5 hydrogen
bond surrogates,6 γAA-peptides,7 D-peptides,8 α,α-disubstituted amino acids,9 N-amino
pep-tides,10 and β-turn mimics.11 More methods are still needed since peptide-based
pharmaceuticals still have not reached large-scale commercial usage.12 Additionally,
since modifications could easily change peptide structure and perhaps render them
useless, it is important that we find more methods so that we can effectively stabilize a
wide variety of peptides.
The method that our lab is exploring to stabilize peptides is α,β-dehydroamino
acids (ΔAAs) (Figure 1). ΔAAs are not included in the canonical 20 amino acids but
there are some organisms that use them. For example, our lab’s interest in them stems
from our work in synthesizing Yaku’amide A (Figure 2), a ΔAA-containing peptide from
the sea sponge Ceratopsion.13 Our synthesis of this anticancer peptide14 has inspired us
to explore more fully the application and synthesis of ΔAAs. In other work, we have also
been exploring new methods for converting these β-hydroxy amino acids into ΔAAs.15

Figure 1. Regular amino acid (left) and
α,β-Dehydroamino acid (right)
2
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Figure 2. Yaku’amide A
We have also studied how ΔAAs stabilize peptides. The main mechanism by
which ΔAAs reduce peptide susceptibility to proteolysis is by maintaining the peptide in
its folded conformation. Allylic strain (Figure 3) between the R group and the peptide
backbone is the main force responsible for holding the peptide’s conformation since it
favors folded conformations by destabilizing unfolded conformations. In particular,
ΔAAs stabilize turns. We have shown this in our lab through work with β turns16 and
incipient 3-10 helices.17 In both cases we included ΔAAs at key positions in the turns
then tested the model peptides in a proteolysis assay. Results showed that some of the
ΔAAs we tried did increase how long the peptides lasted in our assay, with ΔVal (Figure
4) being the most effective. Surprisingly, ΔEnv (Figure 5) was not as effective although
it was bulkier. This is presumably due to its increased flexibility.

Figure 3. A1,3 Strain

Figure 4. ΔVal
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Figure 5. ΔEnv

My work specifically has been with hexafluoro ΔVal (Figure 6). We recently
began exploring fluorinated versions of the ΔAAs that proved most effective in previous
experiments to see what impact the fluorination would have on peptide structure. We
hypothesized that since fluorine is very small, it is unlikely to affect the allylic strain
aspect of peptide stabilization. Its high electronegativity, however, could influence the
electron density of the molecule in new and interesting ways. Initial molecular modeling
simulations gave us predicted Ramachandran plots of ΔVal and F6ΔVal (Figure 7) with
the two plots having clear differences in their preferred ϕ angles (horizontal axis). The ϕ
(psi) angle represents the rotation around the bond between the α-carbon and amide
nitrogen (Figure 8), so an angle closer to zero as predicted in the ΔF6-Val Ramachandran
plot would imply a more planar structure than seen in ΔVal. This gave us the justification
to begin work synthesizing and testing F6ΔVal compounds.

Figure 6. ΔF6-Val

Figure 7. Ramachandran Plots
(blue = low energy, red = high energy)

Figure 8. ϕ and ψ angles

We hope this work will expand the options that medicinal chemists have for
making effective peptide-based pharmaceuticals. If F6ΔVal can impart the same
4

proteolytic stability that ΔVal can but in different secondary structures, then we will have
successfully provided new options for stabilizing peptide drugs.
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Synthesis
My main synthetic goal for this project was a F6ΔVal derivative (Figure 9) that
could be used as a model for some initial structural tests. This molecule was identified as
a target since ΔVal was the most effective of the normal ΔAAs. The acyl group on one
end and dimethyl amide on the other end allow us to examine the structural effects of the
hexafluoro addition in the context of an amino acid capped by amide bonds. We planned
to perform x-ray crystallography studies as well as NMR structural studies on the target
molecule and then compare it to data from previous studies on ΔVal18 to see how the
hexafluoro addition changed the structure.

Figure 9. My Target
In order to synthesize this compound, we decided on following the general
strategy shown in Scheme 1. It begins with the synthesis of a hydroxycarbamate that gets
turned into a mesyloxycarbamate. These carbamates are then used in an
aminohydroxylation reaction to simultaneously install our β-hydroxy group and our CBz
protected N-terminus. From here the molecule is hydrogenated to deprotect the amine,
then acylated to complete the N-terminus. Next the ester is hydrolyzed in preparation for
an azlactone formation reaction. This azlactone is then opened with a dimethylamine to
give the final product.

6

Scheme 1. Planned Synthesis of ΔF6-Val for X-ray Crystallography Studies

The first two steps, carbamate synthesis, are fairly common in our lab since the
mesyloxycarbamate is key to the aminohydroxylation reaction that gives us β-hydroxy
amino acids that can be turned into ΔAAs. First though, we need to form the
hydroxycarbamate (Figure 10). This is done by protecting a hydroxylamine with
benzylchloroformate in the presence of sodium bicarbonate. The crude product is then
recrystallized by dissolving it in dichloromethane and then adding hexanes and leaving it
in the refrigerator. If the product is especially pure, hexanes alone can sometimes be
7

enough to cause it to crystallize. This reaction routinely gave yields of over 80%, with
the best yield being 96%.

Figure 10. Hydroxycarbamate
The second step in creating the mesyloxycarbamate is mesylating the
hydroxycarbamate (Figure 11). This reaction was a bit more problematic than the first
but still worked more often than not. This reaction is achieved by deprotonating the
hydroxycarbamate under basic conditions, then adding the mesylchloride dropwise at low
temperature. The mesylchloride is added cold and slow because it is possible to form the
dimesylated product (Figure 12) under certain conditions. For example, in one of my
earlier attempts at this reaction I miscalculated how much mesylchloride to add and
conducted the reaction with excess mesylchloride, giving almost exclusively the useless
dimesylated carbamate.

Figure 11. Mesyloxycarbamate
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Figure 12. Dimesylated Compound

Once the product is formed, it is purified in much the same way as the
hydroxycarbamate. This recrystallization is more complicated, though, as the impurities
present will come out alongside the product as an oil if not enough dichloromethane or
too much hexanes are used. Due to the difficulty of recrystallization and the nature of the
reaction itself, my yield was lower than that of the hydroxycarbamate, generally around
50-60%, although a particularly good run gave a yield of 80%. Since starting materials
are easy to come by and we perform these reactions on multigram scales, lower yields are
not a major issue.
With the mesyloxycarbamate in hand I could then perform the
aminohydroxylation reaction (Figure 13). This is one of the central reactions our lab does
because it produces the β-hydroxy amino acids that we use in other projects and that we
dehydrate to form the ΔAAs I work with. The reaction involves an addition of a CBz
protected amine and a hydroxy group across the double bond of a commercially available
enoate. This all happens at 47°C with an osmium catalyst. Purification of the crude
product is straightforward since there are no major byproducts formed. An initial low
yield on the aminohydroxylation led me to increase the amount of mesyloxycarbamate
9

used to 1.4 equivalents which increased later yields somewhat. Final yields were
generally in the 40-50% range.

Figure 13. Aminohydroxylation

The next step, hydrogenation (Figure 14), was the first one that gave me any real
trouble. Normally our method for removing CBz protecting groups is a 3-day process
with Pd/C under 600 psi H2. When I first got to this point though, our lab had recently
lost one of our two hydrogenation vessels so the remaining one was in high demand and I
tried a new procedure. This method uses Pd/C and ammonium formate for 4 hours
although, unlike the 3 day procedure, it does require running a column. This method
worked great on the β-hydroxy valine compound I was also working with at the time and
regularly gave over 90% yield, so I expected it would work well with my hexafluoro βhydroxy valine. Unfortunately, it did not. Over a few tries I managed to get a maximum
of 13% yield and even then it was not totally pure. I eventually went back to the 3-day
procedure which worked well and gave 88% yield after filtering through Celite.
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Figure 14. Hydrogenation Methods

Acylation worked immediately but with a minor complication (Figure 15). By
treating the deprotected compound with triethylamine and acetic anhydride for 4 hours I
hoped to install an acyl group on the N-terminus. After running a column I only saw one
spot on the TLC so I assumed I had purified the acylated product, but when I acquired
NMR spectra I saw two compounds in the FNMR. After analyzing FNMR, HNMR and
HMBC I concluded that the β-hydroxy group was also acylated in the byproduct. Since
the diacylated compound was difficult to separate from the desired product by column
and because the next step, hydrolysis, should remove the extra acyl group, I decided to
continue without additional purification.
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Figure 15. Acylation

Hydrolysis (Figure 16) is where things hit a wall. I first tried a base-catalyzed
hydrolysis with lithium hydroxide, but my initial attempt gave a crude mixture that
showed no fluorine in the NMR so we hypothesized that the compound may have
undergone a retro aldol reaction. The next attempt still had fluorine present and no ethyl
peaks in the HNMR but was otherwise still very messy. I took it through the next two
steps but was unable to find anything resembling the final product so I tried a different
method. Our lab has also regularly used trimethyl tin hydroxide for hydrolysis and so I
tried that. Unfortunately, the results were very similar. NMR spectra showed that some
runs were able to remove the ethyl peaks but there were far more byproducts than we
expected from this reaction. I still took the resulting mixture through the final steps but
did not see any promising results.
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Figure 16. Hydrolysis

The final two proposed steps involved an azlactone ring formation and opening
(Figure 17). This is a common method our lab has used on other projects to
simultaneously form an amide bond and create the α,β-double bond. We form the
azlactone with acetic anhydride and sodium acetate for 24 hours, then open it without
purification with DMAP, triethylamine and an amine nucleophile (in my case
dimethylamine). This step has worked well on other compounds in the past so I hoped to
use this reaction to see if my compound had been successfully hydrolyzed. Since this
step forms the key double bond, it should cause a significant shift in the FNMR spectrum
that I could use to determine if the reaction worked. FNMR of the crude product showed
exactly the same peaks as the hydrolysis product, so I concluded that the hydrolysis had
failed.
13

Figure 17. Azlactone Formation and Opening
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Conclusion/Results
As the project currently stands, I was unable to fully synthesize and characterize
my target compound. I was, however, able to make solid progress toward my target and
along the way synthesize and characterize some novel compounds. The
aminohydroxylation product and acylation product in particular were new advances from
this project.
In addition to the new compounds, I also introduced our lab to fluorine NMR.
FNMR has been incredibly useful in this project since it allowed me to monitor major
changes to my compound without having to worry about contaminants. It also helped me
identify ratios of products to byproducts since each compound had predictable double
peaks. Finally, it would make identifying my final product easier since forming the
double bond should cause a large shift in the FNMR.
Moving forward, I plan to try a modified synthetic strategy. Since the hydrolysis
was the problematic step, I will proceed as originally planned up through the acylation
step. Then from there I will dehydrate the compound to form the α,β-double bond. We
have been working on new dehydration methods in our lab so I have plenty of options to
try. From there I can attempt hydrolysis again in a different context, hopefully allowing
it to work, then proceed to attach the dimethylamine with traditional coupling methods.
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